Samsung BioLogics seeks to raise up to $2.5 billion from IPO

Samsung BioLogics Co., Samsung’s contract drug manufacturing unit, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.